Journal of Clinical Oncology, Vol 8, 1050-1055, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

CJ Logothetis, FH Dexeus, L Finn, A Sella, RJ Amato, AG Ayala and RG Kilbourn
Department of Medical Oncology, University of Texas MD Anderson Cancer Center, Houston 77030.

To evaluate the relative efficacy of cisplatin, cyclophosphamide, and Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH) (CISCA) versus methotrexate, vinblastine, Adriamycin, and cisplatin (MVAC), a prospective randomized trial was performed in patients with advanced metastatic urothelial tumors. Patients were stratified by histologic disease type and degree of tumor dissemination. Equal distribution of the clinical characteristics was achieved. One hundred ten patients with metastatic disease of the urinary tract (86 bladder, 16 renal pelvis, seven ureter, one prostatic urethra) met eligibility criteria and were enrolled on study. These represented 82% of the total patients seen during the study period in the Section of Genitourinary Oncology who met the eligibility criteria. The combined complete and partial response rate was significantly higher for patients treated with MVAC than for those treated with CISCA (65% v 46%; P less than .05). The survival duration of MVAC-treated patients was significantly longer than that of CISCA-treated patients (mean, 62.6 weeks; median, 48.3; range, 5.0+ to 162.3+ v mean, 40.4 weeks; median, 36.1; range, 7+ to 147.1+). We conclude that MVAC chemotherapy is superior to CISCA chemotherapy, achieving a higher response rate and a longer survival for equivalent patients with metastatic urothelial tumors.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. I. Milowsky, D. M. Nanus, F. C. Maluf, S. Mironov, W. Shi, A. Iasonos, J. Riches, A. Regazzi, and D. F. Bajorin Final Results of Sequential Doxorubicin Plus Gemcitabine and Ifosfamide, Paclitaxel, and Cisplatin Chemotherapy in Patients With Metastatic or Locally Advanced Transitional Cell Carcinoma of the Urothelium J. Clin. Oncol., September 1, 2009; 27(25): 4062 - 4067. [Abstract] [Full Text] [PDF]

				C. Sweeney, D. F. Bajorin, and C. N. Sternberg Muscle-invasive Bladder Cancer: What Have We Learned and What's New on the Horizon? ASCO Educational Book, January 1, 2008; 2008(1): 200 - 208. [Abstract] [Full Text] [PDF]

				J Carles, E Esteban, M Climent, A Font, J. Gonzalez-Larriba, A Berrocal, I Garcia-Ribas, X Marfa, X Fabregat, J Albanell, et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer Ann. Onc., August 1, 2007; 18(8): 1359 - 1362. [Abstract] [Full Text] [PDF]

				F. Perabo and S. Muller New agents for treatment of advanced transitional cell carcinoma Ann. Onc., May 1, 2007; 18(5): 835 - 843. [Abstract] [Full Text] [PDF]

				J. A. Garcia and R. Dreicer Systemic Chemotherapy for Advanced Bladder Cancer: Update and Controversies J. Clin. Oncol., December 10, 2006; 24(35): 5545 - 5551. [Abstract] [Full Text] [PDF]

				R Sawhney, D Bourgeois, and U. Chaudhary Neo-adjuvant chemotherapy for muscle-invasive bladder cancer: a look ahead Ann. Onc., September 1, 2006; 17(9): 1360 - 1369. [Abstract] [Full Text] [PDF]

				S. M. Cohen, A. Goel, J. Phillips, R. D. Ennis, and M. L. Grossbard The Role of Perioperative Chemotherapy in the Treatment of Urothelial Cancer Oncologist, June 1, 2006; 11(6): 630 - 640. [Abstract] [Full Text] [PDF]

				A. Bamias, I. Tiliakos, M.-D. Karali, and M. A. Dimopoulos Systemic chemotherapy in inoperable or metastatic bladder cancer Ann. Onc., April 1, 2006; 17(4): 553 - 561. [Abstract] [Full Text] [PDF]

				M. D. Galsky and H. I. Scher Bladder Cancer "Adjuvant-Lite": Tastes Great (works as well) and Less Filling (less toxic)? J. Clin. Oncol., August 1, 2005; 23(22): 4823 - 4826. [Full Text] [PDF]

				J. Lehmann, M. Retz, C. Wiemers, J. Beck, J. Thuroff, C. Weining, P. Albers, D. Frohneberg, T. Becker, P.-J. Funke, et al. Adjuvant Cisplatin Plus Methotrexate Versus Methotrexate, Vinblastine, Epirubicin, and Cisplatin in Locally Advanced Bladder Cancer: Results of a Randomized, Multicenter, Phase III Trial (AUO-AB 05/95) J. Clin. Oncol., August 1, 2005; 23(22): 4963 - 4974. [Abstract] [Full Text] [PDF]

				J. Li, B. Juliar, C. Yiannoutsos, R. Ansari, E. Fox, M. J. Fisch, L. H. Einhorn, and C. J. Sweeney Weekly Paclitaxel and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium: A Phase II Hoosier Oncology Group Study J. Clin. Oncol., February 20, 2005; 23(6): 1185 - 1191. [Abstract] [Full Text] [PDF]

				S. Takahashi, M. Suzuki, H. Kume, S. Matsumoto, N. Okamoto, H. Nishimatsu, K. Tomita, and T. Kitamura Combination Chemotherapy of Docetaxel, Ifosfamide and Cisplatin (DIP) in Patients with Metastatic Urothelial Cancer: a Preliminary Report Jpn. J. Clin. Oncol., February 1, 2005; 35(2): 79 - 83. [Abstract] [Full Text] [PDF]

				T. Tsukamoto, H. Kitamura, A. Takahashi, and N. Masumori Treatment of Invasive Bladder Cancer: Lessons from the Past and Perspective for the Future Jpn. J. Clin. Oncol., June 1, 2004; 34(6): 295 - 306. [Abstract] [Full Text] [PDF]

				A. Bamias, G. Aravantinos, C. Deliveliotis, D. Bafaloukos, C. Kalofonos, N. Xiros, A. Zervas, D. Mitropoulos, E. Samantas, D. Pectasides, et al. Docetaxel and Cisplatin With Granulocyte Colony-Stimulating Factor (G-CSF) Versus MVAC With G-CSF in Advanced Urothelial Carcinoma: A Multicenter, Randomized, Phase III Study From the Hellenic Cooperative Oncology Group J. Clin. Oncol., January 15, 2004; 22(2): 220 - 228. [Abstract] [Full Text] [PDF]

				D. Bajorin The Phase III Candidate: Can We Improve the Science of Selection? J. Clin. Oncol., January 15, 2004; 22(2): 211 - 213. [Full Text] [PDF]

				H. B. Grossman, R. B. Natale, C. M. Tangen, V.O. Speights, N. J. Vogelzang, D. L. Trump, R. W. d. White, M. F. Sarosdy, D. P. Wood Jr., D. Raghavan, et al. Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer N. Engl. J. Med., August 28, 2003; 349(9): 859 - 866. [Abstract] [Full Text] [PDF]

				B. M. Mian, C. P. N. Dinney, C. E. Bermejo, P. Sweeney, C. Tellez, X. D. Yang, J. M. Gudas, D. J. McConkey, and M. Bar-Eli Fully Human Anti-Interleukin 8 Antibody Inhibits Tumor Growth in Orthotopic Bladder Cancer Xenografts via Down-Regulation of Matrix Metalloproteases and Nuclear Factor-{kappa}B Clin. Cancer Res., August 1, 2003; 9(8): 3167 - 3175. [Abstract] [Full Text] [PDF]

				A. O. Siefker-Radtke, R. E. Millikan, S.-M. Tu, D. F. Moore Jr, T. L. Smith, D. Williams, and C. J. Logothetis Phase III Trial of Fluorouracil, Interferon Alfa-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer J. Clin. Oncol., March 1, 2002; 20(5): 1361 - 1367. [Abstract] [Full Text] [PDF]

				D. Pectasides, J. Glotsos, N. Bountouroglou, A. Kouloubinis, N. Mitakidis, N. Karvounis, N. Ziras, and A. Athanassiou Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial Ann. Onc., February 20, 2002; 13(2): 243 - 250. [Abstract] [Full Text] [PDF]

				D. J. Vaughn, C. M. Broome, M. Hussain, J. C. Gutheil, and A. B. Markowitz Phase II Trial of Weekly Paclitaxel in Patients With Previously Treated Advanced Urothelial Cancer J. Clin. Oncol., February 15, 2002; 20(4): 937 - 940. [Abstract] [Full Text] [PDF]

				N. J. Vogelzang Neoadjuvant MVAC: The Long and Winding Road Is Getting Shorter and Straighter J. Clin. Oncol., October 15, 2001; 19(20): 4003 - 4004. [Full Text] [PDF]

				A. A. Meluch, F. A. Greco, H. A. Burris III, T. O'Rourke, G. Ortega, R. G. Steis, L. H. Morrissey, V. Johnson, and J. D. Hainsworth Paclitaxel and Gemcitabine Chemotherapy for Advanced Transitional-Cell Carcinoma of the Urothelial Tract: A Phase II Trial of the Minnie Pearl Cancer Research Network J. Clin. Oncol., June 15, 2001; 19(12): 3018 - 3024. [Abstract] [Full Text] [PDF]

				C. N. Sternberg, P. H.M. de Mulder, J. H. Schornagel, C. Theodore, S. D. Fossa, A. T. van Oosterom, F. Witjes, M. Spina, C. J. van Groeningen, C. de Balincourt, et al. Randomized Phase III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924 J. Clin. Oncol., May 15, 2001; 19(10): 2638 - 2646. [Abstract] [Full Text] [PDF]

				M. Hussain, U. Vaishampayan, W. Du, B. Redman, and D. C. Smith Combination Paclitaxel, Carboplatin, and Gemcitabine Is an Active Treatment for Advanced Urothelial Cancer J. Clin. Oncol., May 1, 2001; 19(9): 2527 - 2533. [Abstract] [Full Text] [PDF]

				G. F. Fleming, J. M. Fowler, S. E. Waggoner, L. J. Copeland, B. E. Greer, I. Horowitz, G. Sutton, R. J. Schilder, P. M. Fracasso, H. G. Ball, et al. Phase I Trial of Escalating Doses of Paclitaxel Combined With Fixed Doses of Cisplatin and Doxorubicin in Advanced Endometrial Cancer and Other Gynecologic Malignancies: A Gynecologic Oncology Group Study J. Clin. Oncol., February 15, 2001; 19(4): 1021 - 1029. [Abstract] [Full Text] [PDF]

				M. H. Cohen, M. Rothmann, H. von der Maase, and A. M. Hayden Gemcitabine and Cisplatin for Advanced, Metastatic Bladder Cancer J. Clin. Oncol., February 15, 2001; 19(4): 1229 - 1231. [Full Text]

				J. Bellmunt, V. Guillem, L. Paz-Ares, J. L. Gonzalez-Larriba, J. Carles, E. Batiste-Alentorn, A. Saenz, M. Lopez-Brea, A. Font, M. Nogue, et al. Phase I-II Study of Paclitaxel, Cisplatin, and Gemcitabine in Advanced Transitional-Cell Carcinoma of the Urothelium J. Clin. Oncol., September 18, 2000; 18(18): 3247 - 3255. [Abstract] [Full Text] [PDF]

				H. von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, M.J. Moore, I. Bodrogi, P. Albers, A. Knuth, C.M. Lippert, et al. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study J. Clin. Oncol., September 17, 2000; 18(17): 3068 - 3077. [Abstract] [Full Text] [PDF]

				K. Inoue, J. W. Slaton, D. W. Davis, D. J. Hicklin, D. J. McConkey, T. Karashima, R. Radinsky, and C. P. N. Dinney Treatment of Human Metastatic Transitional Cell Carcinoma of the Bladder in a Murine Model with the Anti-Vascular Endothelial Growth Factor Receptor Monoclonal Antibody DC101 and Paclitaxel Clin. Cancer Res., July 1, 2000; 6(7): 2635 - 2643. [Abstract] [Full Text]

				D. Kaufman, D. Raghavan, M. Carducci, E. G. Levine, B. Murphy, J. Aisner, T. Kuzel, S. Nicol, W. Oh, and W. Stadler Phase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer J. Clin. Oncol., May 9, 2000; 18(9): 1921 - 1927. [Abstract] [Full Text] [PDF]

				P. M. Dodd, J. A. McCaffrey, S. Hilton, M. Mazumdar, H. Herr, W. K. Kelly, E. Icasiano, M. G. Boyle, and D. F. Bajorin Phase I Evaluation of Sequential Doxorubicin Gemcitabine Then Ifosfamide Paclitaxel Cisplatin for Patients With Unresectable or Metastatic Transitional-Cell Carcinoma of the Urothelial Tract J. Clin. Oncol., February 14, 2000; 18(4): 840 - 840. [Abstract] [Full Text] [PDF]

				D. F. Bajorin, P. M. Dodd, M. Mazumdar, M. Fazzari, J. A. McCaffrey, H. I. Scher, H. Herr, G. Higgins, and M. G. Boyle Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy J. Clin. Oncol., October 1, 1999; 17(10): 3173 - 3181. [Abstract] [Full Text] [PDF]